News | Pulmonary Embolism | November 03, 2015

Study Examines Anticoagulants as Outpatient Treatment for Stable Pulmonary Embolism

Trial will monitor low-risk PE patients to see if rivaroxaban reduces time in the hospital, recurrent events and healthcare costs
 

pulmonary embolism, low-risk PE, rivaroxaban, Xarelto, MERCURY PE trial

Image courtesy of Philips Healthcare

November 3, 2015 — Pulmonary embolism (PE) is a potentially life-threatening condition that occurs, for example, when a blood clot travels to the lungs. It requires immediate medical attention and often hospitalization, which in turn leads to higher costs for both patients and healthcare providers. Now, a new trial based on recent research is examining the benefits of treating low-risk pulmonary embolism (PE) patients with rivaroxaban (Xarelto) and discharging them early from the hospital to complete treatment at home.

The trial, called MERCURY PE (MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department), is a randomized, open-label, parallel-group study of 300 PE patients that is being conducted in 45 centers in the United States.

The primary endpoint is the total number of days in the hospital in the first 30 days for the treatment of PE or deep vein thrombosis (DVT), whether for a primary event or a recurrence. Secondary endpoints include: recurrence of non-fatal and fatal blood clots (PE or DVT); number of unplanned hospital visits for PE/DVT symptoms and/or bleeding; any other hospitalization; and patient-reported outcomes. Associated costs also will be evaluated.

"Hospitals across the U.S. have varying protocols in place for managing patients with pulmonary embolism, but the typical standard of care requires the patient to be admitted to the hospital for treatment, which drives up costs," said Paul Burton, M.D., Ph.D., vice president, medical affairs, Janssen Pharmaceuticals. “The MERCURY PE trial will specifically look at how PE patients identified as low-risk are managed, and if these patients have fewer overall hospital days, less events and lower costs when treated with rivaroxaban and immediately discharged compared to patients admitted and given standard treatment."

MERCURY PE builds on prior research, including a recently published study conducted by Jeffery Kline, M.D., of Indiana Health University that found that low-risk PE or DVT patients, when prescribed Xarelto and immediately discharged, had no recurrent events while on therapy. Additionally, no major or clinically relevant bleeding events were observed. A companion study found that low-risk PE/DVT patients who were prescribed Xarelto had significantly lower medical costs than those admitted and given standard treatment.

MERCURY PE is part of the EXPLORER global cardiovascular research program for Xarelto.

For more information: www.clinicaltrials.gov

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Overlay Init